BioNTech SE (BNTX:NASDAQ) closed at $91.17 on October 20, 2026, up 2.20% on the day. The stock trades 26.5% below its 52-week high of $124.00 and 14.7% above its 52-week low of $79.52. Over the past year, it lost 17.4%. BioNTech SE is part of the Health Care sector.
In 252 trading sessions since October 20, 2025, BNTX closed higher on 120 days (48%). Its best day was August 19, 2026 (+21.96%) and its worst was March 10, 2026 (-17.88%). The stock moved 10% or more in a single session 3 times. It opened at least 5% above the previous day's high 1 time.
BioNTech SE is a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases. Its cutting-edge pipeline includes individualized mRNA-based product candidates, chimeric antigen receptor T cells, novel checkpoint immunomodulators, targeted cancer antibodies, and small molecules. The company's operating segment includes Clinical; Technology Platform; Manufacturing; Product Sales and External Services and Business Service. It generates maximum revenue from the Manufacturing segment.
Find more stocks like BNTX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.